1-4 of 4
Meijing Zheng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Orelabrutinib plus rituximab-based chemoimmunotherapy regimens in relapsed or refractory marginal zone lymphoma: A multicentric phase II trial

Free
Shaohua Wu, Li Ma, Jingrong Wang, Xiaolian Wen, Meijing Zheng, Bing Xu, Hongling Ma, Yanli Wang, Liping Su
Journal: Blood
Blood (2025) 146 (Supplement 1): 7117.
https://doi.org/10.1182/blood-2025-7117
Published: 2025
Journal Articles

Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDPM) in Relapsed/Refractory diffuse large B-cell lymphoma: A multicenter, single-arm study

Free
Li Ma, Jin Zhao, Jingrong Wang, Bing Xu, Meijing Zheng, Junyuan Lang, Xiaolian Wen, Bin Yang, Shaohua Wu, Yanli Wang, Li Liang, Liping Su
Journal: Blood
Blood (2025) 146 (Supplement 1): 5476.
https://doi.org/10.1182/blood-2025-5476
Published: 2025
Journal Articles

Study on the Bone Marrow Plasma Cell Percentage in Predicting Survival in Newly Diagnosed Multiple Myeloma

Free
Tao Guan, Meijing Zheng, Liping Su
Journal: Blood
Blood (2024) 144 (Supplement 1): 6984.
https://doi.org/10.1182/blood-2024-206521
Published: 2024
Journal Articles

Mitoxantrone Hydrochloride Liposome (Lipo-MIT) Combined with R-GDP Regimen in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Single-Arm Study

Free
Li Ma, Jin Zhao, Jingrong Wang, Meijing Zheng, Xiaolian Wen, Junyuan Lang, Bin Yang, Liping Su
Journal: Blood
Blood (2024) 144 (Supplement 1): 6506.
https://doi.org/10.1182/blood-2024-205306
Published: 2024